Albany, NY (PRWEB) February 01, 2015 -- The new report is titled ‘Recombinant Coagulation Factors 2015: Maturation of Recombinant Clotting Factor Pipeline and Emergence of Gene Therapy and Alternative Procoagulants’ and deals with historical statistics and future projections regarding the recombinant coagulation factors market. It gathers data from 2013 and the first three quarters of 2014 to analyze the development of the market through the two years. It focuses strongly on pipeline products in the market.
To get sample report with TOC Click Here: http://www.researchmoz.com/enquiry.php?type=sample&repid=241916
Recombinant coagulation factors are used in diseases such as hemophilia A and B, to bring about blood coagulation when the patient’s natural capacity to do so has been hampered. Market data for various classes of recombinant coagulation factors such as factors VII, VIII, and IX are analyzed in the research report, along with an examination of the development of other nascent and comparatively untouched substances and methods such as alternative procoagulants, immune tolerance-inducing agents, and gene therapeutics.
The report profiles the competitive landscape in detail and provides special attention to the impact of new products on the respective positions of major players of the market. This helps gain insight into the short-to-mid-term future of the market. Trends gaining strength in the market are also carefully examined, according to their potential impact on the market stats and competitive landscape.
To Browse a Full Report with TOC: http://www.researchmoz.us/recombinant-coagulation-factors-2015-maturation-of-recombinant-clotting-factor-pipeline-and-emergence-of-gene-therapy-and-alternative-procoagulants-report.html
The field of gene therapeutics, or gene therapy, is a strong emergent alternative to recombinant coagulation factors. New technologies in the gene therapy field are examined in detail, as are the major players intending to strengthen their presence in this sector. Keeping with this theme, the competitive advantages of alternative procoagulants and gene therapy are listed and analyzed.
The sales and market size of four major types of recombinant coagulation factors are analyzed in the report: rFVIII, rFIX, rFVII, and thrombin. Within the market analysis of rFVIII, specific medicines such as Helixate, Kogenate, Advate/Recombinate, etc. are analyzed deeper to understand their particular market size data. Likewise, the market data for medicines such as Benefix and Alprolix, which constitute the recombinant factor IX category, and NovoSeven and Coagil VII, which make up the recombinant factor VII category, are also examined in detail. The recombinant factor Thrombin is analyzed as a separate category.
Among pipeline projects, two distinct classes can be formed: wild-type recombinant factors and long-acting recombinant factors. Research into all types of recombinant factors, i.e., rFVIII, rFIX, and rFVII is ongoing to produce wild and long-acting varieties of each. The present market conditions for each are also described in the report, giving a clear idea of the trajectory from the present market conditions to the pipeline projects.
The report also profiles major pharmaceutical companies active in the recombinant coagulants market. These include giants such as Baxter, CSL, Novo Nordisk, Bayer HealthCare Pharmaceuticals, Biogen Idec, AstraZeneca, etc.
All Reports of this Category Here: http://www.researchmoz.us/therapeutic-area-market-reports-37.html
Call 866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales(at)researchmoz(dot)us
Michelle Thoras, ResearchMoz, http://www.researchmoz.us/, +1-518-618-1030, [email protected]
Share this article